Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company, is developing next-generation immunotherapy with a multi-tumor-specific T-cell platform to overcome limitations of current T-cell therapies with narrow target recognition. This approach, which recognizes multiple antigens within the tumor, helps prevent tumor resistance and adaptation. Marker is participating in the APOLLO trial testing this broad spectrum of target recognition in lymphoma patients who have relapsed after CAR-T CD19 therapy while also exploring acute myeloid leukemia and pancreatic cancer.

Juan explains, "Without a doubt, the earlier products that have been approved, such as mainly chimeric T-cell receptors, have validated the clinical power of T-cells in their ability to recognize and kill cancer cells. I think that no one will argue that, and this has been something that has been well evaluated, particularly in hematologic malignancies and particularly in lymphoma."

"However, there are limitations with these types of technologies, and some of the limitations now have become more and more obvious a few years after the approval of those initial drugs. One of the main limitations relies on the short-term clinical benefit observed in many cases once patients receive these therapies. That can be attributed largely to the narrow target recognition of these initial strategies."

"Our approach is different and seeks to overcome this particular limitation. The way that we seek to do so is by creating a product that is capable of recognizing multiple antigens present within the tumor. In that particular way, our therapy is capable of preventing this mechanism of tumor adaptation and tumor resistance. We hope that this multi-target approach will lead to clinical responses that will be long-sustained and durable in comparison to what we're seeing initially with these initial studies or initial drugs that have been approved in the market."

#MarkerTherapeutics #Oncology #AutologousCellTherapy #TCellTherapy #Lymphoma #Cancer

markertherapeutics.com

Listen to the podcast here